Join to access to all OVN content. Join for Free
Patients as a key stakeholder for scientific conferences
patient involvement in scientific congresses patient advocate in research ISMPP podcasts medical and patient engagement juvenile arthritis awareness patient voice in healthcare

Patients as a key stakeholder for scientific conferences


Share This Article


In this episode of Informed, guest host Dawn Lobban is joined by Simon Stones, an experienced patient advocate and senior medical writer. They discuss the topic of patients at scientific congresses and conferences. Simon shares his journey of being diagnosed with juvenile arthritis and inflammatory bowel disease as a child, which inspired him to learn about his conditions and work to help others by amplifying the patient voice in research. Tune in to gain insights into the why, how, and where of patient involvement in scientific congresses – what it looks like now and what it could be in the future. Guest host Dawn Lobban, Medical and Patient Engagement Consultant is joined by Simon Stones, Senior Medical Writer, Envision Pharma Group for this episode of InformED.

If you enjoyed this podcast, please watch the related ISMPP U titled Patients in Focus: Redefining Scientific Conference Dynamics found on our ISMPP U and eLearning site, https://www.pathlms.com/ismpp/courses/60368. ISMPP U’s are free to members.

Produced by ISMPP (International Society for Medical Publication P rofessionals), in partnership with Evergreen Podcasts. The views expressed in this recording are those of the individuals and do not necessarily reflect the opinions of ISMPP or the companies or institutions with which they are affiliated. This presentation is for informational purposes only and is not intended as legal or regulatory advice. Special Thanks to the University of Pittsburgh Journal of Healthcare Informatics Research ACL (Association of Computational Linguistics) AMIA (American Medical Informatics Association). Thank you for listening to InformED! Please subscribe to the show on your favorite podcast app and rate our show highly if you enjoyed it. For more information, visit ismpp.org.

Click for Source
patient involvement in scientific congresses, patient advocate in research, ISMPP podcasts, medical and patient engagement, juvenile arthritis awareness, patient voice in healthcare

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions
OVN Avatar Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH

Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions

Article
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
OVN Avatar Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, Gaëlle Guyaderb, Lotfi Boudalib, Nicolas Albin

Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years

Article
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review
OVN Avatar Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS

Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review

Article
Transforming oncology: Five frontiers driving progress in cancer care
Partner Avatar iNIZIO

Transforming oncology: Five frontiers driving progress in cancer care

Article
Virtual Oncology MSL Team Increases KOL Engagement by 120%
Partner Avatar iNIZIO

Virtual Oncology MSL Team Increases KOL Engagement by 120%

Article
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
OVN Avatar Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis

Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis

Explore OVN